D
David Vydra
Researcher at Palacký University, Olomouc
Publications - 7
Citations - 664
David Vydra is an academic researcher from Palacký University, Olomouc. The author has contributed to research in topics: Cucurbitacins & Gene. The author has an hindex of 4, co-authored 7 publications receiving 602 citations. Previous affiliations of David Vydra include Charles University in Prague.
Papers
More filters
Journal ArticleDOI
Pharmacological activities of natural triterpenoids and their therapeutic implications
Petr Dzubak,Marian Hajduch,David Vydra,Alica Hustova,Miroslav Kvasnica,David Biedermann,Lenka Marková,Milan Urban,Jan Sarek +8 more
TL;DR: The pharmacological activity of naturally occurring triterpenoids excluding the degraded triter penoids and cucurbitacins is reviewed, which includes anticancer, anti-inflammatory, antiulcerogenic, antimicrobial and antiviral activity.
Journal ArticleDOI
Batch immunoextraction method for efficient purification of aromatic cytokinins.
Eva Hauserová,Jana Swaczynová,Karel Doležal,René Lenobel,Igor Popa,Marian Hajduch,David Vydra,K. Fuksová,Miroslav Strnad +8 more
TL;DR: A batch immunoextraction method was developed and optimized for the purification of 2OH3MeOBAPR from murine blood samples, and the high efficacy and simplicity of this method for the isolation of target analytes from biological material is demonstrated.
Journal ArticleDOI
Fetal colon cell line FHC exhibits tumorigenic phenotype, complex karyotype, and TP53 gene mutation
Karel Souček,Pavla Gajdušková,Marie Brázdová,Martina Hýzd'alová,Lenka Kočí,David Vydra,Radek Trojanec,Zuzana Pernicová,Lenka Lentvorská,Marian Hajduch,Jirina Hofmanova,Alois Kozubík +11 more
TL;DR: Mutation of TP53 gene was associated with abolished induction of p21(Waf1/Cip1 and MDM-2 proteins and resistance to apoptosis after genotoxic treatment, and FHC cells can be considered a valuable experimental model for various studies.
Journal Article
In vivo mode of action of CYC116, a novel small molecule inhibitor of Aurora kinases and VEGFR2
TL;DR: The results confirm that CYC116 acts as a dual mitotic and angiogenesis inhibitor in vivo, a combination of anti-proliferative mechanisms which could have therapeutic benefit in the clinic.
Book ChapterDOI
Cyclin‐Dependent Kinase Inhibitors and Cancer: Usefulness of Proteomic Approaches in Assessment of the Molecular Mechanisms and Efficacy of Novel Therapeutics
Marian Hajduch,Helena Kupcova Skalnikova,Petr Halada,David Vydra,Petr Dzubak,Marta Dziechciarkova,Miroslav Strnad,Danuta Radioch,Suresh Jivan Gadher,Hana Kovarova +9 more